Danish pharmaceutical company Novo Nordisk announced on September 16 its partnership with Anthropic, leveraging its scientific platform Claude Science to accelerate new drug discovery. On the same day, China's GenScript Biotech announced a collaboration with Lilly TuneLab™, Eli Lilly's AI/machine learning drug discovery collaboration platform, to provide wet lab validation services. Additionally, according to Hard AI, ByteDance's spun-off AI drug discovery company, Anew Labs, has completed a $290 million seed round of financing, with participation from institutions such as Sequoia China, Hillhouse, and IDG. Driven by these positive developments, China's A-share innovative drug industry chain performed actively, with Nearshore Proteins hitting a 20CM daily limit and BPS Bioscience rising 10.37%. The CRO sector also showed strong performance, with Wanbang Biopharma increasing over 14%, and Hong Kong-listed GenScript Biotech surging 13.76%.